Lumretuzumab

DB12683InvestigationalProtein Based Therapies

Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Code names: RO5479599

Resolves to

Compound

UNIIY6M3205516CAS1448327-63-6

Targets

P21860ERBB3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lumretuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account